Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
GLP-1 受體激動劑單獨及與 SGLT2 抑制劑聯合使用在 2 型糖尿病中的心血管、腎臟及安全性結果:系統性回顧與統合分析。
Circulation 2024-08-30
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.
Sacubitril/Valsartan 對心衰竭全因住院的影響:PARADIGM-HF 和 PARAGON-HF 隨機臨床試驗的事後分析。
JAMA Cardiol 2024-08-30
Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy.
阻塞性睡眠呼吸暫停相關高血壓:文獻回顧與臨床管理策略。
Hypertens Res 2024-08-29
Qualitative Evaluation to Understand Barriers and Facilitators to Prescribing Angiotensin Receptor-Neprilysin Inhibitors (ARNi) and Sodium-Glucose Cotransporter Inhibitors (SGLT2i) in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
質性評估以了解在射血分數降低的心臟衰竭(HFrEF)患者中開立血管緊張素受體-中性酯酶抑制劑(ARNi)和鈉-葡萄糖共轉運蛋白抑制劑(SGLT2i)的障礙與促進因素。
J Am Pharm Assoc (2003) 2024-08-29
Accelerometer-Measured Physical Activity in Patients with Heart Failure and Reduced Ejection Fraction: Determinants and Relationship with Patient-Reported Health Status.
心衰竭及射血分數降低患者的加速度計測量身體活動:決定因素及與患者自報健康狀態的關係。
Am Heart J 2024-08-29
Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database.
2型糖尿病患者使用鈉-葡萄糖共轉運蛋白-2抑制劑 (SGLT2i) 的普遍性及治療:基於意大利初級保健數據庫的評估。
Acta Diabetol 2024-08-29
Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease.
鈉-葡萄糖共轉運蛋白 2 抑制劑對糖尿病及晚期慢性腎病患者心血管和腎臟結果的影響。
Diabetologia 2024-08-29
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.
在使用 SGLT2 抑制劑的超重或肥胖、糖尿病及 HFpEF 患者中,GLP-1 受體激動劑的應用。
JACC Heart Fail 2024-08-29